Skip to main content

Breast Cancer Research and Treatment

Ausgabe 2/2011

Inhalt (37 Artikel)

Review

Pregnancy after breast cancer: if you wish, ma’am

Olivia Pagani, Ann Partridge, Larissa Korde, Sunil Badve, John Bartlett, Kathy Albain, Richard Gelber, Aron Goldhirsch

Preclinical study

Molecular classification of breast phyllodes tumors: validation of the histologic grading scheme and insights into malignant progression

Mei Kim Ang, Aik Seng Ooi, Aye Aye Thike, Patrick Tan, Zhongfa Zhang, Karl Dykema, Kyle Furge, Bin Tean Teh, Puay Hoon Tan

Preclinical study

Crosstalk between nicotine and estrogen-induced estrogen receptor activation induces α9-nicotinic acetylcholine receptor expression in human breast cancer cells

Chia-Hwa Lee, Ya-Chieh Chang, Ching-Shyang Chen, Shih-Hsin Tu, Ying-Jan Wang, Li-Ching Chen, Yu-Jia Chang, Po-Li Wei, Hui-Wen Chang, Chien-Hsi Chang, Ching-Shui Huang, Chih-Hsiung Wu, Yuan-Soon Ho

Preclinical study

Biologic role of activated leukocyte cell adhesion molecule overexpression in breast cancer cell lines and clinical tumor tissue

Sibyll Hein, Volkmar Müller, Nadine Köhler, Harriet Wikman, Sylke Krenkel, Thomas Streichert, Michaela Schweizer, Sabine Riethdorf, Volker Assmann, Maike Ihnen, Katrin Beck, Rana Issa, Fritz Jänicke, Klaus Pantel, Karin Milde-Langosch

Preclinical study

Ras-related protein 1 and the insulin-like growth factor type I receptor are associated with risk of progression in patients diagnosed with carcinoma in situ

Dana K. Furstenau, Nandita Mitra, Fei Wan, Robert Lewis, Michael D. Feldman, Douglas L. Fraker, Marina A. Guvakova

Preclinical study

Expression of Abl interactor 1 and its prognostic significance in breast cancer: a tissue-array-based investigation

Chunjie Wang, Danh Tran-Thanh, Juan C. Moreno, Thomas R. Cawthorn, Lindsay M. Jacks, Dong-Yu Wang, David R. McCready, Susan J. Done

Preclinical study

The PI3 kinase/mTOR blocker NVP-BEZ235 overrides resistance against irreversible ErbB inhibitors in breast cancer cells

Caroline Brünner-Kubath, Waheed Shabbir, Victoria Saferding, Renate Wagner, Christian F. Singer, Peter Valent, Walter Berger, Brigitte Marian, Christoph C. Zielinski, Michael Grusch, Thomas W. Grunt

Preclinical study

Economic issues involved in integrating genomic testing into clinical care: the case of genomic testing to guide decision-making about chemotherapy for breast cancer patients

Patricia Marino, Carole Siani, François Bertucci, Henri Roche, Anne-Laure Martin, Patrice Viens, Valérie Seror

Preclinical Study

Inhibition of the c-fms proto-oncogene autocrine loop and tumor phenotype in glucocorticoid stimulated human breast carcinoma cells

Eugene P. Toy, Tiffany Lamb, Masoud Azodi, William J. Roy, Ho-Hyung Woo, Setsuko K. Chambers

Preclinical study

Aberrant expression of DNA damage response proteins is associated with breast cancer subtype and clinical features

Gulnur Guler, Cigdem Himmetoglu, Rafael E. Jimenez, Susan M. Geyer, Wenle P. Wang, Stefan Costinean, Robert T. Pilarski, Carl Morrison, Dinc Suren, Jianhua Liu, Jingchun Chen, Jyoti Kamal, Charles L. Shapiro, Kay Huebner

Preclinical study

Nuclear co-localization and functional interaction of COX-2 and HIF-1α characterize bone metastasis of human breast carcinoma

Paola Maroni, Emanuela Matteucci, Alessandro Luzzati, Giuseppe Perrucchini, Paola Bendinelli, Maria Alfonsina Desiderio

Clinical trial

Artificial neural network analysis of circulating tumor cells in metastatic breast cancer patients

Antonio Giordano, Mario Giuliano, Michelino De Laurentiis, Antonio Eleuteri, Francesco Iorio, Roberto Tagliaferri, Gabriel N. Hortobagyi, Lajos Pusztai, Sabino De Placido, Kenneth Hess, Massimo Cristofanilli, James M. Reuben

Clinical Trial

Surgery of the primary tumor does not improve survival in stage IV breast cancer

Laura Dominici, Julie Najita, Melissa Hughes, Joyce Niland, Paul Marcom, Yu-ning Wong, Bradford Carter, Sara Javid, Stephen Edge, Harold Burstein, Mehra Golshan

Epidemiology

A nomogram to predict survival time in women starting first-line chemotherapy for advanced breast cancer

C. K. Lee, M. Hudson, M. Stockler, A. S. Coates, S. Ackland, V. Gebski, S. Lord, M. Friedlander, F. Boyle, R. J. Simes

Epidemiology

Bulky DNA adducts and breast cancer risk in the prospective EPIC-Italy study

Calogero Saieva, Marco Peluso, Giovanna Masala, Armelle Munnia, Marco Ceroti, Sara Piro, Francesco Sera, Benedetta Bendinelli, Valeria Pala, Sabina Sieri, Rosario Tumino, Maria Concetta Giurdanella, Salvatore Panico, Amalia Mattiello, Paolo Vineis, Silvia Polidoro, Giuseppe Matullo, Domenico Palli

Epidemiology

Dietary fiber is associated with circulating concentrations of C-reactive protein in breast cancer survivors: the HEAL study

Adriana Villaseñor, Anita Ambs, Rachel Ballard-Barbash, Kathy B. Baumgartner, Anne McTiernan, Cornelia M. Ulrich, Marian L. Neuhouser

Epidemiology

Survival in breast cancer patients with bone metastases and skeletal-related events: a population-based cohort study in Denmark (1999–2007)

Mellissa Yong, Annette Østergaard Jensen, Jacob Bonde Jacobsen, Mette Nørgaard, Jon P. Fryzek, Henrik Toft Sørensen

Epidemiology

Adipose levels of polybrominated diphenyl ethers and risk of breast cancer

Susan Hurley, Peggy Reynolds, Debbie Goldberg, David O. Nelson, Stefanie S. Jeffrey, Myrto Petreas

Epidemiology

TNF-alpha polymorphisms and breast cancer

Yu Yang, Rennan Feng, Sheng Bi, Yuqing Xu

Epidemiology

Associations of physical activity with quality of life and functional ability in breast cancer patients during active adjuvant treatment: the Pathways Study

Jeanne S. Mandelblatt, Gheorghe Luta, Marilyn L. Kwan, Solomon B. Makgoeng, Isaac J. Ergas, Janise M. Roh, Barbara Sternfeld, Lucile L. Adams-Campbell, Lawrence H. Kushi

Epidemiology

Replication of five GWAS-identified loci and breast cancer risk among Hispanic and non-Hispanic white women living in the Southwestern United States

Martha L. Slattery, Kathy B. Baumgartner, Anna R. Giuliano, Tim Byers, Jennifer S. Herrick, Roger K. Wolff

Epidemiology

The use of atypical antipsychotics and the risk of breast cancer

Laurent Azoulay, Hui Yin, Christel Renoux, Samy Suissa

Epidemiology

Examining the influence of beta blockers and ACE inhibitors on the risk for breast cancer recurrence: results from the LACE cohort

Patricia A. Ganz, Laurel A. Habel, Erin K. Weltzien, Bette J. Caan, Steven W. Cole

Epidemiology

Cancer risk in Jewish BRCA1 and BRCA2 mutation carriers: Effects of oral contraceptive use and parental origin of mutation

Shiri Bernholtz, Yael Laitman, Bella Kaufman, Shani Paluch Shimon, Eitan Friedman

Epidemiology

Obesity and breast cancer survival in ethnically diverse postmenopausal women: the Multiethnic Cohort Study

Shannon M. Conroy, Gertraud Maskarinec, Lynne R. Wilkens, Kami K. White, Brian E. Henderson, Laurence N. Kolonel

Epidemiology

Androgen receptor polyglutamine tract length in Egyptian male breast cancer patients

Samuel F. Gilbert, Amr S. Soliman, Maria Iniesta, Mohab Eissa, Ahmed Hablas, Ibrahim A. Seifeldin, Ashley Strahley, Mousumi Banerjee, Sofia D. Merajver

Epidemiology

Common genetic variation in adiponectin, leptin, and leptin receptor and association with breast cancer subtypes

Sarah J. Nyante, Marilie D. Gammon, Jay S. Kaufman, Jeannette T. Bensen, Dan Yu Lin, Jill S. Barnholtz-Sloan, Yijuan Hu, Qianchuan He, Jingchun Luo, Robert C. Millikan

Brief Report

Biologic markers determine both the risk and the timing of recurrence in breast cancer

Laura J. Esserman, Dan H. Moore, Pamela J. Tsing, Philip W. Chu, Christina Yau, Elissa Ozanne, Robert E. Chung, Vickram J. Tandon, John W. Park, Frederick L. Baehner, Stig Kreps, Andrew N. J. Tutt, Cheryl E. Gillett, Christopher C. Benz

Brief Report

Evaluation of associations between common variation in mitotic regulatory pathways and risk of overall and high grade breast cancer

Kristen N. Stevens, Xianshu Wang, Zachary Fredericksen, V. Shane Pankratz, James Cerhan, Celine M. Vachon, Janet E. Olson, Fergus J. Couch

Brief Report

Simultaneous measurement of ERα, HER2, and PhosphoERK1/2 in breast cancer cell lines by flow cytometry

Ulas Darda Bayraktar, Tae Kon Kim, Katherine Drews-Elger, Cara Benjamin, Dorraya El-Ashry, Eric Wieder, Krishna V. Komanduri

Brief Report

Two patients with germline mutations in both BRCA1 and BRCA2 discovered unintentionally: a case series and discussion of BRCA testing modalities

Ann Marie Augustyn, Nicole M. Agostino, Tara L. Namey, Suresh Nair, Martin A. Martino

Brief Report

PIK3CA mutations rarely demonstrate genotypic intratumoral heterogeneity and are selected for in breast cancer progression

Kevin Kalinsky, Adriana Heguy, Umeshkumar K. Bhanot, Sujata Patil, Mary Ellen Moynahan

Letter to the Editor

Need for clarification of data in the recent meta-analysis about RAD51 135G>C polymorphism and breast cancer risk

Xiao-Feng He, Jiao Su, Ying Zhang, Da-Peng Ding, Wei Wang, Yi Liu

Letter to the Editor

Association of XPC polymorphisms with breast cancer risk

Feng Xu, Dewu Zhong, Zhonghua Tang, Meirong Zhou, Yu Zhu

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.